MX2021013822A - Virus de fiebre amarilla atenuado y usos del mismo para el tratamiento de cancer. - Google Patents

Virus de fiebre amarilla atenuado y usos del mismo para el tratamiento de cancer.

Info

Publication number
MX2021013822A
MX2021013822A MX2021013822A MX2021013822A MX2021013822A MX 2021013822 A MX2021013822 A MX 2021013822A MX 2021013822 A MX2021013822 A MX 2021013822A MX 2021013822 A MX2021013822 A MX 2021013822A MX 2021013822 A MX2021013822 A MX 2021013822A
Authority
MX
Mexico
Prior art keywords
treatment
fever virus
yellow fever
cancer
attenuated yellow
Prior art date
Application number
MX2021013822A
Other languages
English (en)
Inventor
Ying Wang
Charles Stauft
John Robert Coleman
Steffen Mueller
Original Assignee
Codagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codagenix Inc filed Critical Codagenix Inc
Publication of MX2021013822A publication Critical patent/MX2021013822A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención es el uso de virus recombinantes diseñados para el tratamiento de formas de virus de tumores malignos utilizando el virus de Fiebre Amarilla atenuado. El método de la presente invención es particularmente útil para el tratamiento de tumores malignos en varios órganos, tal como: mama, piel, colon, pasaje bronquial, revestimiento epitelial del tracto gastrointestinal, respiratorio superior y genitourinario, hígado, próstata y el cerebro. Se han demostrado remisiones asombrosas en animales experimentales para el tratamiento del cáncer de mama y el melanoma.
MX2021013822A 2019-05-15 2020-05-14 Virus de fiebre amarilla atenuado y usos del mismo para el tratamiento de cancer. MX2021013822A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962848443P 2019-05-15 2019-05-15
PCT/US2020/032901 WO2020232254A1 (en) 2019-05-15 2020-05-14 Attenuated yellow fever virus and uses thereof for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2021013822A true MX2021013822A (es) 2021-12-14

Family

ID=73289285

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013822A MX2021013822A (es) 2019-05-15 2020-05-14 Virus de fiebre amarilla atenuado y usos del mismo para el tratamiento de cancer.

Country Status (11)

Country Link
US (1) US20220241359A1 (es)
EP (1) EP3969047A4 (es)
JP (1) JP2022531976A (es)
KR (1) KR20220008317A (es)
CN (1) CN113874032A (es)
BR (1) BR112021022733A2 (es)
CA (1) CA3139328A1 (es)
IL (1) IL288096A (es)
MX (1) MX2021013822A (es)
SG (1) SG11202112328TA (es)
WO (1) WO2020232254A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
JP3934673B1 (ja) * 2003-06-18 2007-06-20 ジェネラックス・コーポレイション 修飾組換えワクシニアウイルスおよびその他の微生物、その使用
EP1586330A1 (en) * 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
BRPI0504945B8 (pt) * 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
WO2013138670A1 (en) * 2012-03-15 2013-09-19 Icahn School Of Medicine At Mount Sinai Yellow fever virus ns5 mutants as flavivirus vaccine candidates
CN108064176A (zh) * 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
WO2017197207A1 (en) * 2016-05-11 2017-11-16 Ohio State Innovation Foundation Oncolytic viruses comprising esrage and methods of treating cancer

Also Published As

Publication number Publication date
BR112021022733A2 (pt) 2022-02-01
US20220241359A1 (en) 2022-08-04
SG11202112328TA (en) 2021-12-30
CN113874032A (zh) 2021-12-31
EP3969047A4 (en) 2022-11-09
EP3969047A1 (en) 2022-03-23
JP2022531976A (ja) 2022-07-12
KR20220008317A (ko) 2022-01-20
CA3139328A1 (en) 2020-11-19
IL288096A (en) 2022-01-01
WO2020232254A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
GEP20237466B (en) Methods of inhibiting angiogenesis in patient
HRP20210200T1 (hr) Kombinirana antitumorska imunoterapija
MX2021003389A (es) Metodos para tratar el cancer.
MX2020006530A (es) Virus recombinante con region desoptimizada de par de codones y usos del mismo para el tratamiento de cancer.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
CY1120300T1 (el) Αντισωματα ειδικα στην κλαουδινη 6 (cldn6)
EA201890730A1 (ru) Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
MX2019011148A (es) Metodos de tratamiento.
MY193727A (en) Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
BR112013029212A2 (pt) anticorpos para o tratamento de câncer expressando claudina-6
UA122526C2 (uk) Сполуки 1-тетрагідропіранілкарбоніл-2,3-дигідро-1h-індолу для лікування раку
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
MX2022008100A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
NZ726365A (en) Combinations for treating cancers
WO2016123591A3 (en) Compositions and methods for treatment and detection of cancers
ZA201907225B (en) Treatment of her2 positive cancers
JOP20210164A1 (ar) طرق وتركيبات علاج السرطان
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
IL288939A (en) Methods of treating cancer by targeting cold tumors
WO2009124281A3 (en) Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
MX2021003262A (es) Metodos de tratamiento.
MX2021013822A (es) Virus de fiebre amarilla atenuado y usos del mismo para el tratamiento de cancer.